Search

Your search keyword '"Zannad, F."' showing total 1,854 results

Search Constraints

Start Over You searched for: Author "Zannad, F." Remove constraint Author: "Zannad, F."
1,854 results on '"Zannad, F."'

Search Results

2. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

5. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: Results from a phase 3 randomized, double-blind, placebo-controlled trial

6. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

8. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study

9. Clinic Versus Ambulatory Blood Pressure in Resistant Hypertension: Impact of Antihypertensive Medication Nonadherence: A Post Hoc Analysis the DENERHTN Study

11. Unsupervised clustering to differentiate rheumatoid arthritis patients based on proteomic signatures

14. NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patients

15. Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction – EMPEROR-Preserved trial

18. NON-ADHERENCE TO ANTIHYPERTENSIVE TREATMENT IS A MAJOR DETERMINANT OF THE CLINIC-AMBULATORY BP DIFFERENCE IN PATIENTS WITH RESISTANT HYPERTENSION

19. Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions

20. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology

21. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

22. Telomere length is independently associated with all-cause mortality in chronic heart failure

23. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction

24. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

25. Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure

27. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

28. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

29. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial

31. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

32. Cardiovascular and renal outcomes with empagliflozin in heart failure

39. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

40. Significant Long-term Variations in Left Ventricular Ejection Fraction Driven by Systemic Vascular Resistance Changes

41. Development, validation and implementation of biomarker testing in cardiovascular medicine state-of-the-art: Proceedings of the European Society of Cardiology - Cardiovascular Round Table

42. The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure

43. Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF

44. Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure

45. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients with Heart Failure by Baseline Diabetes Status: Results from the EMPEROR-Reduced Trial

46. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: The EMPEROR-Reduced trial

47. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial

48. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure across the Spectrum of Kidney Function: Insights from EMPEROR-Reduced

49. Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction

50. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced

Catalog

Books, media, physical & digital resources